Lupin signs licensing agreement with Alvion to market cardiometabolic drugs

5 Apr 2022 , 12:43 PM

By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin said it will play a significant role in improving the quality of healthcare and access to medicines.

Commenting on the announcement, Gabriel Georgy, Regional Head Southeast Asia of Lupin said, ?Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system. Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region. We look forward to expanding our partnership with Alvion over the coming years.?

Lupin is a transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The companys consolidated net profit jumped 24.47% to Rs 545.52 crore on a 3.57% rise in total revenue from operations to Rs 4160.93 crore in Q3 FY22 over Q3 FY21.

Shares of Lupin were trading 0.32% lower at Rs 787.55 on BSE.

Powered by Capital Market – Live News